"High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. 
INTRODUCTION
The prognosis for relapsing/refractory neuroblastoma (RRNB) remains dismal, with a 5-year disease-free survival (DFS) of less than 20%, and no effective salvage treatment has been identified so far. Palliation is often the sole option for recurrent disease after myeloablative treatment, because salvage therapy may not be feasible or justified due to no realistic chance for cure (1, 2) . Treatment of RRNB is still experimental and focused on introducing novel cytotoxic and/or tumor-targeted biological agents. and autologous hematopoietic stem cell transplantation (ASCT) was practicable and associated with limited toxicity (4, 5) . However, only 36% of the patients responded, and the 3-year event-free survival (EFS) rate was 0.31 ± 0.10.
Studies have not shown any advantage in using HLA-identical donors for allogeneic stem cell transplantation (allo-SCT) to treat high-risk NB (6) (7) (8) . Also, it has been postulated that absence of graft-versus-host disease (GvHD) in allo-SCT is a major obstacle to an antitumor effect. Haploidentical stem cell transplantation (haplo-SCT) for treatment of malignant diseases has become an established procedure (9) (10) (11) , which has also proven to be feasible and involve acceptable toxicity in children with hematological malignancies (10) . Although reports concerning haplo-SCT for pediatric solid tumors are still anecdotal, a potential graftversus-tumor (GvT) effect in such cases has been discussed (12) (13) (14) .
Considering the mentioned findings, we studied the influence of high-dose 131 I-MIBG treatment followed by reduced intensity conditioning (RIC) with haplo-SCT in a series of consecutive RRNB patients that, to the best of our knowledge, constitute the largest cohort of such patients treated with this combined approach.
PATIENTS AND METHODS

Patient Population
The treatment used was designed for RRNB patients aged 1-18 years who develop resistant disease at any time. This study was approved by the Lund University Ethical Review
Board for Research Involving Humans (DNr 385/2005), and informed consent was obtained from all parents/guardians.
Mobilization and Processing of Peripheral Blood Progenitor Cells
At the time the treatment protocol was developed, it was suggested that the mobilization of peripheral blood progenitor cells is more effective in male donors (15, 16) . To be able to harvest the optimal number of CD34+ cells, which is particularly important due to additional cell loss caused by further processing of the graft, we chose to transplant all our patients with cells from an HLA haploidentical father. Typing was performed at the two-digit level for 
Culture of Mesenchymal Stem Cells
To facilitate engraftment and reduce the risk of GvHD, mesenchymal stem cells (MSCs)
were transplanted directly after hematopoietic stem cell infusion (18) . The MSCs were cultured as described elsewhere (19) . Briefly, heparinized bone marrow (45-60 mL) was aspirated from the iliac crest of the haploidentical donor 4 weeks before transplantation.
Ficoll-isolated mononuclear cells were seeded in complete mesenchymal stem cell medium, which was changed after 3 days and weekly thereafter. On the day of haplo-SCT, MSCs were harvested, washed, and resuspended in 0.9% saline supplemented with 5% human serum albumin. Flow cytometry showed expression of typical surface marker profiles. 
Infusion of
Donor Lymphocyte Infusion
After terminating immunosuppression, donor lymphocyte infusions (DLIs) were planned to improve immune reconstitution and/or to convert mixed chimerism (MC) to complete donor chimerism (CC). The initial number of infused CD3+ lymphocytes was 2.5-5 x 10 cells/kg/dose. The intention was to increase the dose of CD3+ cells if no GvHD occurred. For details, see Table 3 . Blood for a DLI was obtained from the donor on the day of the infusion.
No GvHD prophylaxis was given after DLI.
Post-Transplant Intrathecal Liposomal Cytarabine
A patient with CNS relapse was given intrathecal liposomal cytarabine every 4-6 weeks for up to 1 year after transplantation.
Engraftment, Immunological Reconstitution, and Chimerism Analysis
Engraftment was defined as the first of 3 consecutive days with an absolute neutrophil 
Supportive Care
No G-CSF was administered post-transplant. Prophylactic voriconazole and valacyclovir were given for 6 months after transplantation. As oral prophylaxis against Pneumocystis carinii pneumonia, trimethoprim-sulfamethoxazole was instituted for 6 months following engraftment. Surveillance of CMV, AdV, EBV, and BK viral loads was achieved by PCR performed weekly up to day +100, and preemptive therapy was initiated if increasing loads were detected.
Evaluation of Disease Response
In accordance with the International Neuroblastoma Response Criteria (21), evaluation of disease markers and imaging studies in combination with bilateral bone marrow aspirations and biopsies were performed at regular intervals of 4-6 weeks for the first 6 months and thereafter every 3-6 months.
RESULTS
Patient Characteristics
Between June 2005 and November 2005, five patients with stage IV RRNB were eligible for inclusion in the study. These children (given unique patient numbers NB01-NB05) had been intensively pretreated at the Department of Pediatric Oncology, University
Hospital, Lund, Sweden, three of them with high-dose chemotherapy and ASCT. One of the patients had developed secondary AML that had been successfully treated. One had achieved complete remission before haplo-HSCT (CR 2), three were in partial remission (PR), and one had progressive disease (progression). The median interval between initial diagnosis and haplo-HSCT was 3.9 years (Table 1) .
Graft Composition
A median of 13 x 10 6 CD34+ cells/kg were transplanted with a median of 0.98 x 10 5 graft-contaminating CD3+ cells (Table 2) . A median of 0.75 x 10 6 MSCs/kg were transplanted directly after hematopoietic stem cell infusion (Table 2) .
High-Dose 131 I-MIBG and RIC
High-dose 131 I-MIBG treatment was feasible, and infusion was done at a median dose of 10.9 mCi/kg, corresponding to a median WB absorbed dose of 1.6 Gy ( Table 3 ). The patient whose bone marrow was infiltrated with NB cells at the time of treatment (NB-02) had prolonged post-MIBG marrow aplasia that persisted until the beginning of RIC, whereas the other children recovered their blood counts before start of conditioning. The RIC caused no serious adverse effects.
Hematological Recovery
Neutrophil engraftment was achieved in all five children. The median time to ANC recovery was 13 days (range: 11-16 days), and the median time to platelet recovery, which occurred in four patients, was 12 days (range: 11-37 days) ( Table 2) . One patient (NB-02) rejected the graft on day 18, and an attempt to rescue the graft by intensified immunosuppression and stem cell boost failed. That child eventually recovered after autologous backup.
Chimerism Analysis of T-Cell Compartment
Although chimerism analysis was performed in different cell populations, DLI interventions were driven by chimerism analysis of the T-cell compartment (CD3+ cells).
Patient NB-02, who rejected the graft, exhibited complete donor chimerism (CC) at the time of engraftment. Patient NB-01 showed sustained CC at all time points. In the remaining three patients, analysis of CD3+ cells revealed increasing mixed donor chimerism (MC) after initial CC, which was eventually converted to CC status.
Patient NB-03 displayed a decline to 93% donor chimerism 6 weeks posttransplant and received DLI treatment. Transient conversion to CC was achieved, but, despite that, only recipient T-cells were detectable 9 weeks after transplant. ATG treatment was instituted, and the patient successfully regained CC. In patient NB-04, donor chimerism declined to 40% 6 weeks post-transplant, and that child was given DLI and regained sustained CC by week 10. Patient NB-05 showed a decline to 8% donor chimerism by week 5 posttransplant, despite "preemptive" DLI. Additional DLIs were given, and the peripheral blood CD3+ cells gradually increased to CC by week 9. Chimerism analysis is presented in Figure   1 .
Immune Reconstitution
Quantitative analysis was performed on T, B, and NK lymphocytes from four of the 
DISCUSSION
Neuroblastoma has an incidence of about 10 cases per million children aged 0-14 years, and hence it is the most common pediatric extracranial solid tumor (22) . It accounts for 7.8% of all childhood malignancies, and it is the third leading cause of death due to cancer (23) .
The prognosis is particularly poor in children suffering from metastatic disease combined with other risk factors (e.g., age > 1 year, amplification of the MYCN oncogene, and unfavorable histology). Even in cases involving complete remission followed by high-dose chemotherapy and ASCT, the 3-year EFS is less than 35% (24). The prognosis is also very dismal for highrisk patients who fail frontline therapy, and it is unlikely that such individuals will benefit from high-dose therapy (25) . Furthermore, in studies of therapy-resistant NB patients (7, 26) , it was found that survival was not improved by high-dose chemotherapy followed by ASCT Another option might be to exploit T-cell-mediated cytotoxicity. Traditionally, it has been assumed that NB cells, which apparently lack expression of HLA class I, are not susceptible to the cytotoxic effect elicited by T-cells. However, a post-transplant cytokine storm can cause NB cells to begin expressing HLA class I and thereby make them potential targets for T-cells. Therefore, we speculate that GvHD-induced cytokine release can have a similar effect. Moreover, it has been suggested that some NB cells may be selected to survive and progress by expressing either higher or lower levels of MHC class I antigens in order to resist
NK-or T-cell-mediated anti-tumor responses, respectively (36).
It has also been shown that NB cell lines are susceptible to killing by differentiated CD8+
CTL clones in an MHC class-I-non-restricted manner (38) . Thus tumor cells in vivo might be recognized and attacked by haploidentical T-cells after transplantation. Perhaps activation of this mechanism can be applied to initiate/enhance death pathways, so that they can subsequently redirect nonspecific T-cells of DLI origin towards NB cells, and in that way be of therapeutic value.
The results of allo-SCT from HLA-identical related donors have been disappointing (6, 8) ,
but the association between GvHD and effectiveness was not assessed in the cited studies. All the patients in those investigations received standard GvHD prophylaxis, and the incidence of GvHD was low among transplanted patients with no scheduled DLI. Accordingly, apart from HLA identity, that therapeutic setting was oriented towards effective immunosuppression to avoid GvHD, which, in turn, might inhibit GvT.
It is generally acknowledged that the GvT effect is less pronounced when allo-SCT is performed in a patient with a large tumor load. Therefore, to minimize the pre-transplant tumor burden, we administered high-dose MIBG to all five of our patients. Our approach with haplo-SCT followed by immunomodulation has potential advantages, one of which is that the pharmacological GvHD prophylaxis is short compared to other transplant modalities. Also, co-transplantation of donor-derived mesenchymal stem cells is done primarily to reduce the risk of GvHD. We chose that strategy because our present patients' grafts had relatively large numbers of T-cells, and we also wanted to facilitate and enhance engraftment of HLAincompatible hematopoietic cells (18) . Furthermore, low-dose DLI allows induction of a potentially "controllable" GvHD, which is beneficial, since HLA incompatibility might Our treatment strategy is novel and unique, because it is based on targeting of residual disease by high-dose MIBG and RIC chemotherapy combined with induction of a potentially long-lasting immunomediated and a complex GvT effect achieved using haploidentical donor immunocompetent cells. It appears that this approach led to prolonged DFS in two out of five children with otherwise incurable neuroblastoma, although it is a matter of speculation whether the procedure was actually responsible for disappearance of the tumors. Nevertheless, since it is highly unlikely that a durable response can be obtained after giving only a regimen of RIC or after 131 I-MIBG treatment alone, it seems reasonable to assume that the combination of the two procedures, together with implementation of the GvT effect mediated by haploidentical immune systems, contributed to the promising outcomes in two of our five patients. Obviously, this assumption must be confirmed in a larger study. 
